These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24398298)

  • 1. The benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme target.
    Wilkinson C; McPhillie MJ; Zhou Y; Woods S; Afanador GA; Rawson S; Khaliq F; Prigge ST; Roberts CW; Rice DW; McLeod R; Fishwick CW; Muench SP
    Bioorg Med Chem Lett; 2014 Feb; 24(3):911-6. PubMed ID: 24398298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents.
    Muench SP; Prigge ST; McLeod R; Rafferty JB; Kirisits MJ; Roberts CW; Mui EJ; Rice DW
    Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):328-38. PubMed ID: 17327670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
    Afanador GA; Muench SP; McPhillie M; Fomovska A; Schön A; Zhou Y; Cheng G; Stec J; Freundlich JS; Shieh HM; Anderson JW; Jacobus DP; Fidock DA; Kozikowski AP; Fishwick CW; Rice DW; Freire E; McLeod R; Prigge ST
    Biochemistry; 2013 Dec; 52(51):9155-66. PubMed ID: 24295325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.
    Stec J; Fomovska A; Afanador GA; Muench SP; Zhou Y; Lai BS; El Bissati K; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Sommervile C; Woods S; Roberts CW; Rice D; Prigge ST; McLeod R; Kozikowski AP
    ChemMedChem; 2013 Jul; 8(7):1138-60. PubMed ID: 23776166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase.
    Muench SP; Prigge ST; Zhu L; Kirisits MJ; Roberts CW; Wernimont S; McLeod R; Rice DW
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Jun; 62(Pt 6):604-6. PubMed ID: 16754994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
    Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
    Cheng G; Muench SP; Zhou Y; Afanador GA; Mui EJ; Fomovska A; Lai BS; Prigge ST; Woods S; Roberts CW; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Rice DW; McLeod R
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2035-43. PubMed ID: 23453069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.
    Mehboob S; Hevener KE; Truong K; Boci T; Santarsiero BD; Johnson ME
    J Med Chem; 2012 Jun; 55(12):5933-41. PubMed ID: 22642319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).
    Zitko J; Doležal M
    Expert Opin Ther Pat; 2016 Sep; 26(9):1079-94. PubMed ID: 27399249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.
    Mistry TL; Truong L; Ghosh AK; Johnson ME; Mehboob S
    ACS Infect Dis; 2017 Jan; 3(1):54-61. PubMed ID: 27756129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan.
    Otero JM; Noël AJ; Guardado-Calvo P; Llamas-Saiz AL; Wende W; Schierling B; Pingoud A; van Raaij MJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Oct; 68(Pt 10):1139-48. PubMed ID: 23027736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I.
    McLeod R; Muench SP; Rafferty JB; Kyle DE; Mui EJ; Kirisits MJ; Mack DG; Roberts CW; Samuel BU; Lyons RE; Dorris M; Milhous WK; Rice DW
    Int J Parasitol; 2001 Feb; 31(2):109-13. PubMed ID: 11239932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.
    Tipparaju SK; Muench SP; Mui EJ; Ruzheinikov SN; Lu JZ; Hutson SL; Kirisits MJ; Prigge ST; Roberts CW; Henriquez FL; Kozikowski AP; Rice DW; McLeod RL
    J Med Chem; 2010 Sep; 53(17):6287-300. PubMed ID: 20698542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition.
    Maity K; Bhargav SP; Sankaran B; Surolia N; Surolia A; Suguna K
    IUBMB Life; 2010 Jun; 62(6):467-76. PubMed ID: 20503440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of antimicrobials into parasites.
    Samuel BU; Hearn B; Mack D; Wender P; Rothbard J; Kirisits MJ; Mui E; Wernimont S; Roberts CW; Muench SP; Rice DW; Prigge ST; Law AB; McLeod R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14281-6. PubMed ID: 14623959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening.
    Nicola G; Smith CA; Lucumi E; Kuo MR; Karagyozov L; Fidock DA; Sacchettini JC; Abagyan R
    Biochem Biophys Res Commun; 2007 Jul; 358(3):686-91. PubMed ID: 17509532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
    Muench SP; Stec J; Zhou Y; Afanador GA; McPhillie MJ; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Prigge ST; Rice DW; McLeod R
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3551-5. PubMed ID: 23664871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.
    Neckles C; Pschibul A; Lai CT; Hirschbeck M; Kuper J; Davoodi S; Zou J; Liu N; Pan P; Shah S; Daryaee F; Bommineni GR; Lai C; Simmerling C; Kisker C; Tonge PJ
    Biochemistry; 2016 May; 55(21):2992-3006. PubMed ID: 27136302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
    Tipparaju SK; Joyasawal S; Forrester S; Mulhearn DC; Pegan S; Johnson ME; Mesecar AD; Kozikowski AP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3565-9. PubMed ID: 18499454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).
    Lu X; Huang K; You Q
    Expert Opin Ther Pat; 2011 Jul; 21(7):1007-22. PubMed ID: 21651455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.